| First Posted | New Trial Filing | Phase | Status |
|---|---|---|---|
| 2026-06-11 | NCT07643623 Neoadjuvant and Adjuvant Therapy Studies of Sintilimab Combined With Chemotherapy With or… | Phase 2/3 | Not Yet Recruiting |
| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 2/3 | |||
| NCT07490262 | A Study to Evaluate the Efficacy and Safety of IBI310 and Sintilimab Combination Therapy… | Hepatocellular Carcinoma (HCC) | Recruiting |
| NCT07643623 | Neoadjuvant and Adjuvant Therapy Studies of Sintilimab Combined With Chemotherapy With or… | Resectable Gastric/Gastroesophageal Junction Adenocarcinoma | Not Yet Recruiting |
| Phase 2 | |||
| NCT07506109 | A Phase II Study of Sintilimab Combined With Ipilimumab N01, Cetuximab and Dabrafenib in… | BRAF V600E | Recruiting |
| NCT07422753 | A Prospective, Randomized Study of TACE Combined With Sintilimab, Bevacizumab, and… | Hepatocellular Carcinoma (HCC) | Recruiting |
| NCT07560488 | Ipilimumab N01 Combined With Sintilimab, Bevacizumab Biosimilar, and Hepatic Arterial… | HCC - Hepatocellular Carcinoma | Recruiting |
| NCT07487662 | TACE or Ablation Combined With Sintilimab and Ipilimumab N01 as Neoadjuvant Therapy for… | Hepato Cellular Carcinoma (HCC) | Not Yet Recruiting |